Akums introduces Hydroxyurea oral suspension for sickle cell disease

Cell TherapyDrug ApprovalImmunotherapy
Akums introduces Hydroxyurea oral suspension for sickle cell disease
Preview
Source: Pharmaceutical Technology
Akums’ new medicine will be sold for sickle cell disease treatment. Credit: kikpokemon / Shutterstock.com.
Indian company Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, the country’s first room temperature-stable drug for treating sickle cell disease, according to a LinkedIn post.
The new formulation offers a cost-effective alternative to imported brands in the country.
Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy.
The existing imported Hydroxyurea solution, which requires refrigeration between 2°C and 8°C, costs Rs77,000 ($928.9) in the Indian market.
Akums’ novel oral suspension drug will be available for Rs600, making it highly accessible to patients.
See Also:
With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL
Akums introduces Hydroxyurea oral suspension for sickle cell disease
Preview
Source: Pharmaceutical Technology
AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline
Akums introduces Hydroxyurea oral suspension for sickle cell disease
Preview
Source: Pharmaceutical Technology
An inherited blood ailment, sickle cell disease changes the red blood cells into a sickle shape, which hampers their ability to transport oxygen across the body effectively.
Hydroxyurea aids red blood cells to maintain a rounder and larger shape, allowing for improved oxygen delivery throughout the body.
In a media statement posted on LinkedIn, Akums Drugs and Pharmaceuticals said: “In alignment with the objectives outlined in the national sickle cell anaemia mission, as announced by the Honourable Prime Minister Shri Narendra Modi Ji, Akums pledges to provide this medicine to the government at less than 1% of the cost of global brand imported in India, thus embodying the spirit of ‘Make in India’ and fostering widespread benefit to the masses.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.